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Breast cancer as a life‐threatening illness can be related to anxiety,
demoralization, or depression,1,2 which can occur at any moment of
the clinical‐diagnostic pathway.
Despite the fact that brain metastases, paraneoplastic syndromes,
or pharmacotherapy might induce mood alterations, spontaneous
hypomanic and manic episodes usually do not occur in patients with
breast cancer.
Concerning mood alterations associated with the administration
of antitumor drugs, orally available, pan‐class I phosphoinositide 3‐
kinase (PI3K) inhibitors, which exert their activity on breast cancer cells
positive for estrogen receptor (ER), particularly in some sub‐popula-
tions (for instance, some PI3K mutations),3 can induce anxiety, eupho-
ria, anhedonia, or depression.4
We report a case of a patient with breast cancer and without a
familial and personal history of mood or anxiety disorders, who experi-
enced a manic episode at the age of 54 during the treatment with an
investigational pan‐class I PI3K inhibitor.
A written informed consent was obtained from the patient for the
publication of this case report. The local Ethical Committee (Comitato
Etico per Parma) approved the double‐blind placebo controlled clinical
trial in which the patient was enrolled (reference number for the
approval, 3553; date of approval, 29/01/2013).2 | CASE REPORT
A 54‐year‐old woman, with a 4‐year history of breast cancer with bone
metastases, was treated with an oral pan‐class I PI3K inhibitorPsycho‐Oncology. 2017;1–3. wileyonlinelibrary.com/journal/p(buparlisib‐BKM120) in a double‐blind placebo‐controlled clinical trial
carried out at the Medical Oncology Unit of the University Hospital
of Parma, Italy.
She was married, and she lived with her husband and with their
31‐year‐old daughter (with motor disability secondary to a pertussis‐
associated encephalitis when she was 2 years old). The global function-
ing was satisfying, and overall the patient adopted good coping strate-
gies for her daughter disability.
She entered the trial on February 28, 2014. No major psychopath-
ological concerns emerged during the first 2 months of treatment,
while at the beginning of May she complained tiredness, avolition,
and demoralization; therefore, the oncologist suggested to take some
days off. When on holidays in Paris, on May 9, she became irritable
and verbally aggressive. Few days later, when back home, she was
hyperactive, easily distractive, talkative, and agitated. Later on, she
became insomniac and developed grandiose self‐esteem, satisfying
the criteria for a full‐blown manic episode.
On May 22, the oncologist referred her to the psychiatry consulta-
tion‐liaison service, where a diagnosis of a manic episode was made.
The patient refused any treatment, and she was sectioned and taken
into the acute psychiatric ward. At the first evaluation, she was
extremely talkative, with flight of ideas, grandiosity, and high
irritability.
The patient was put on Olanzapine 10 mg b.i.d. and Lorazepam
2 mg in the evening both intra‐muscular. The blood tests showed a
mild elevation in levels of the liver enzymes transaminases (AST
55 U/L; ALT 61 U/L) and lactate dehydrogenase (LDH 710 U/L) and
low iron levels (30 μg/dL). The neurological examination was unre-
markable, and the brain computerized axial tomography (CAT) scan
did not show any metastases or acute vascular damage.Copyright © 2017 John Wiley & Sons, Ltd.on 1
Key points
• Breast cancer can induce anxiety, demoralization, or
depression.
• Hypomanic and manic episodes are unusual in patients
with breast cancer.
• PI3K inhibitors have demonstrated antitumoral
effectiveness in breast cancer.
• PI3K inhibitors can be associated with changes in brain
serotonin levels and mental disturbances.
• In this case report, pan‐class I PI3K inhibitor
2 MARCHESI ET AL.In 1 week, her mood condition rapidly improved; Olanzapine
(10 mg b.i.d.) was switched to oral administration, and lorazepam was
discontinued. She was discharged on June 7, and she attended the out-
patients service with psychiatric visits at nearly monthly intervals. One
month after the discharge, she reached criteria for complete remission,
and in order to plan the duration of maintenance treatment with anti-
psychotic, the study allocation has been unblinded.
The patient was in the active drug arm; therefore, the investiga-
tional drug was discontinued, and in September, the Olanzapine dose
was tapered to 10 mg q.d. because the patient complained sedation
and tiredness. After the maintenance of a healthy mental condition,
the antipsychotic was discontinued. The patient passed away because
of breast cancer disease progression in May 2015.
administration was associated with the development of
a manic episode3 | DISCUSSION
Acute hypomania or mania does not usually occur in patients with
breast cancer. Nevertheless, breast cancer and bipolar disorder (BD)
can be associated, because PALB2 and BRCA2 were identified as risk
genes for breast cancer and BD5 and cytokines play a role in breast
cancer development and progression6 and in pathophysiology of BD.7
The occurrence of a manic episode could have different underly-
ing mechanism.
First, according to the stress‐diathesis hypothesis, the emotional
distress caused by a diagnosis of cancer could have triggered the onset
of BD in a vulnerable subject (ie, either a familial history of BD or a pre-
vious onset of the mood disorder). However, this does not look the
case because a previous episode never occurred, nor a familial vulner-
ability to BD was found.
Secondly, a manic episode could have been associated with
brain metastases, which can be found in approximately 10% of
patients with metastatic breast cancer. This condition might be char-
acterized both by behavioral changes, cognitive impairment, and
focal neurological symptoms. In this patient, this possibility was
excluded by the normal neurological examination and the negative
brain CT scan.
Lastly, the manic episode might have been induced by the pharma-
cological treatment for the breast cancer. The search for novel agents
to ensure efficacy with a good tolerability profile is constant. Breast
cancer is frequently associated with the activation of the PI3K/AKT/
mTOR pathway, and its block results in apoptosis and inhibits tumor
cell proliferation, angiogenesis, and metastases.8 In fact, potent pan‐
PI3K inhibitors, which act on all the isoforms of class I PI3K (α, β, ϒ,
and δ), have been shown to be active in preclinical and clinical studies
in breast cancer.4 Interestingly, the same review4 reported that mood
alterations, such as anxiety, euphoria, anhedonia, or depression,
occurred in 17% to 45% of patients treated with this class of drugs.
To explain this effect, it has been hypothesized that the dysregulation
of the PI3K pathway can be associated with changes in serotonin
levels, and, therefore, with mental disturbances such as anxiety and
depression.9
Summarizing, even though we cannot exclude other possible
causes, the timing of symptom development, the negativity of personal
and familial psychiatric history, and the absence of clinical neurologicalfindings or CT scan alterations suggest a treatment‐related manic
episode.
To our knowledge, this is the first report that describes the onset
of a manic episode during treatment with a pan‐class I PI3K inhibitor,
showing that also a severe mood disorder can be induced by this class
of drugs. Our observation, along with previous findings of depression
and anxiety related to this treatment,9 suggest that mental health
should be carefully monitored in patients treated with PI3K inhibitors
and mild mood alterations should be also recognized and properly
treated to prevent the development of severe mood episode.
Isoform‐specific PI3K inhibitors are becoming more and more
popular, because their specificity offers considerable advantages in
terms of both efficacy and safety. Specifically, p110α‐specific PI3K
inhibitors may have the advantage of a neuron‐specific regulation of
class I PI3K catalytic subunits that would make these compounds asso-
ciated with a lower risk of induced‐mood disorders, especially when
compared with pan‐PI3K inhibitors.10
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